The role of consumer health in expanding access to care
Healthcare is evolving. Once confined to clinics and in-office appointments—healthcare is now in our homes, routines, and daily choices. The shift towards accessible healthcare solutions, like over-the-counter (OTC) medicines, is empowering people to manage their health proactively. With 81% of adults using OTC medicines for minor ailments, this societal change saves physicians many hours each year, reducing the strain on healthcare systems.
Despite increasing consumer interest in self-care, critical health categories like pain management, skin cancer, and more remain undertreated, underdiagnosed, and underpenetrated.
The self-care revolution
Consumers are increasingly investing in their health. In the U.S. alone, a staggering 82% of consumers consider health and wellness a leading priority in their lives, contributing to a $480 billion market. This clear sign shows that more people are actively taking charge of their well-being today to build a healthier future.
Yet, accessibility gaps persist. Science and innovation must bridge this gap—not just through new formulations, but through better awareness, education, and application methods. Consumer-focused companies like ours are working to address this.
The power of innovation
Despite skin cancer diagnoses outnumbering all other cancers in the U.S., only 13.5% of adults wear sunscreen daily. Our research found that 99% of healthcare providers believe better application and aesthetics would boost sunscreen use. In response, our R&D teams at Neutrogena developed a new mineral formula that overcame these top consumer barriers with more UVA protection and less whitening compared to competitors, all while providing a lightweight, invisible finish. Our goal is to improve consumers' willingness to wear sunscreen regularly, protecting their skin and health.
While new innovations create a solution to the problem, education is what empowers consumers to pick it up in the aisle. For example, research shows a need for wider education about sun care in schools, so Neutrogena teamed up with Walgreens and the Melanoma Research Foundation to teach students and families the importance of sunscreen use. Programs like this help people understand how to practice preventative care, and its benefits as one of the most powerful tools in reducing health inequities.
Where do we go from here?
Consumer health companies can make a difference—whether through smarter skincare solutions, new pain relief technologies, or improved application methods. Here are three ways to do that.
1. Accessibility must be a priority, not an afterthought
Despite advancements in OTC medicine, inaccessibility remains widespread. According to the World Health Organization, nearly 2 billion people lack reliable access to essential medications, such as acetaminophen in the pain care category. Beyond availability, consumers are also facing unique barriers based on their needs or stage of life. Despite many pain relief options being in pill form, people are often averse to swallowing pills for a variety of reasons ranging from general dislike to fear of choking. To make pain care accessible to more people, this unique need must be front and center in product development.
Our Tylenol teams used this information and philosophy to develop products for several life stages, adding powder packs to make it easier for children to swallow, and a topical pain relief formation for those with skin discomfort Accessibility drove the creation to ensure that more people could get the relief they needed in a way that worked for them.
2. Sustainability is front and center
Consumers today want products that not only enhance personal health but also minimize environmental impact. The future of consumer health is one where science works smarter, faster, and more sustainably, ensuring the well-being of people and the planet.
As part of Kenvue's approach, we developed an internal assessment tool, the Sustainable Innovation Profiler, which helps our product developers select more sustainable ingredients, packaging, and product formats. Integrating this capability into our innovation process should help us meet the rising expectations of consumers, retailers, and regulators, while building a more resilient and sustainable future and driving brand growth.
3. Collaboration is key to expanding everyday care
No single company can solve the accessibility crisis alone. Partnerships between brands, healthcare providers, retailers, and policymakers are essential for meaningful impact.
We do this by partnering with dermatologists, pediatricians, and public health organizations to identify care gaps and address misinformation. By meeting consumers wherever they are—aisles, pharmacies, doctor's offices, or online—we empower them to take charge of their health.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Kraft Heinz Announces Major Change To All Of Their Products Coming Soon
Changes are coming to your favorite Kraft Heinz products. The food company announced Tuesday it will no longer launch any new food products in the U.S. that contain Food, Drug & Cosmetic (FD&C) colors. The company will also remove synthetic colors from all of its existing U.S. products by the end of 2027. 'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio,' says Pedro Navio, North America President at Kraft Heinz. Nearly 90 percent of its U.S. products are already free of FD&C colors. The company removed artificial colors, flavors, and preservatives from its popular Kraft Mac and Cheese in 2016, and its Heinz Tomato Ketchup has never contained artificial dyes. The company says it will remove colors from any products where their absence will not affect consumer experience, replace artificial colors with natural colors, or create new colors when a natural replacement isn't available. Since dyes are used to enhance the color of foods, their removal will not affect the taste of your favorite products. 'Above all, we are focused on providing nutritious, affordable, and great-tasting food for Americans and this is a privilege we don't take lightly,' Navio says. FD&C colors such as Blue No. 1, Yellow No. 5, and Red No. 3 are synthetic color additives approved by the Food and Drug Administration (FDA) to create consistent, vibrant colors in food, drug, and cosmetic products. The FDA revoked the use of Red No. 3 in food and ingested drugs in January, phasing out its use by January 15, 2027. In April, Health and Human Services Secretary Robert F. Kennedy Jr. called for the removal of artificial dyes in U.S. foods. Kraft Heinz says it is continually evolving its recipes and product line to improve nutritional profiles, such as reducing sugar, salt, and saturated fat in more than 1,000 products. It is also encouraging licensees of its brands to remove artificial colors from their products as well. In addition to Kraft and Heinz, the company owns a variety of brands including Jell-O, Oscar Mayer, Philadelphia, Capri Sun, Kool-Aid, Lunchables, and more. Read the original article on Southern Living
Yahoo
31 minutes ago
- Yahoo
‘Poop transplants' have been happening for decades. Now researchers have identified some unintended consequences
Fecal microbiota transplants are common medical procedures dating back decades that can help restore the gut health of people with colon infections - but scientists now warn of newly discovered consequences from the procedure. The 'poop transplant' is the transfer of the stool of a healthy donor to a recipient. The stool contains beneficial bacteria that can improve the patient's gut bacteria, which guards immune health and helps to regulate metabolism. They are approved by the Food and Drug Administration to treat people with common C. diff infections that may cause severe gastrointestinal symptoms and inflammation in hospital patients who have been on antibiotics. Roughly 48,000 procedures are done each year. Now, University of Chicago researchers say a study in mice and experiments with human tissue have revealed some long-lasting and unintended consequences due to transplanting microorganisms from only one section of the digestive tract. 'I think it's a bit of a wakeup call to the field that maybe we shouldn't willy-nilly put large bowel microbes into different parts of the intestine that shouldn't be there,' Dr. Orlando 'Landon' DeLeon, postdoctoral researcher at the university, said in a statement. 'If we're designing good therapeutics, we should be aware of the importance of matching the regional microbiota to their proper environments, so that we provide better overall health benefits.' DeLeon is the lead author of the new research, which was published on Friday in the journal Cell. To reach these conclusions, the authors gave three groups of mice transplants of microorganisms from the middle part of the small intestine that connects to the colon, and a standard fecal transplant from the colon. The test showed that the microorganisms from each transplant were able to colonize the entirety of the intestinal tract in the mice -- not just certain regions. This created what they called regional gut mismatches, lasting for up to three months following a transplant. The microbes also altered their new intestinal environments, 'terraforming' the lining in ways that caused changes in the recipient's metabolism, behavior and energy balance. There were shifts in liver metabolism, including activity in genes associated with immune function. The mice also exhibited different eating behaviors. The gut has several distinct regions with vastly different microbial ecosystems. Imbalances in gut bacteria have been tied to a risk of cancer. 'There are microbes along the entire intestinal tract, and we just study predominately the last third of it (the colon),' DeLeon said. 'So, how can you expect [a transplant], with microbes from a third of the intestinal tract at the end of it, to fix the rest of the intestine?' What this means for human patients may be murky right now, but the authors say more caution is needed with the transplants going forward. They advocate for an approach that would transfer microorganism from all regions of the intestine and not just largely from the colon. In the future, they plan to conduct further study related to how different microbes exert their influence in different parts of the intestine and how the gut regions terraformed by microbiota mismatches can be restored. 'We have absolutely no idea what's in FMT, except that it's a combination of microbes,' Dr. Eugene Chang, the Martin Boyer Professor of Medicine at the university and senior author of the study, said. 'But even a single FMT will cause a change in the host-microbe relationships in these very different regions of the bowel that may be very difficult to reverse.'
Associated Press
33 minutes ago
- Associated Press
Argentines reel from health care cutbacks as President Milei's state overhaul mirrors Trump's
BUENOS AIRES, Argentina (AP) — To outsiders, the Facebook group chat reads like a snarl of nonsensical emojis and letters. To uninsured Argentine cancer patients, it's a lifeline. The surreptitious network connects advocates who have spare drugs to Argentines with cancer who lost access to their treatment in March 2024 when President Javier Milei suspended a federal agency, known as DADSE, that paid for their expensive medications. Whenever Facebook cracks the coded pleas and removes the group for violating its rules on drug sales, another appears, swelling with Argentines who say they've grown sicker since the radical libertarian president took a chainsaw to health care. 'All I need for my body to function is this medication, and Milei is saying, 'There's no money,'' said Ariel Wagener, a 47-year-old pizza chef with leukemia who was hospitalized this year with failing kidneys after losing access to his medication. Without DADSE, a month's worth of his leukemia drug costs $21,000. Wagener's condition stabilized after he got leftover medication via Facebook, donated by a family whose loved one had died of cancer. The halting of millions of dollars of free cancer drugs is just one way Milei's austerity drive has torn through the public health system that once set Argentina apart in Latin America, ensuring that health care was free for pretty much everyone who couldn't afford private insurance. Since taking office in December 2023, Milei has slashed Argentina's health care budget by 48% in real terms. His administration fired over 2,000 Health Ministry employees, including 1,400 over just a few days in January. As part of Milei's plan to remake Argentina's troubled economy and cut waste and bureaucracy, officials gutted the National Cancer Institute, suspending early detection programs for breast and cervical cancer. They froze federal funds for immunization campaigns, hobbling vaccine access as Argentina confronts a measles outbreak for the first time in decades. They dismantled the National Directorate for HIV, Hepatitis and Tuberculosis, leading to testing and treatment delays. They defunded emergency contraception and stopped distributing abortion pills. 'We're seeing setbacks we haven't seen in decades,' said María Fernanda Boriotti, president of Argentina's Federation of Health Professionals. 'HIV patients without treatment, cancer patients dying for lack of medication, hospitals without resources, health professionals pushed out of the system.' The government curtailed medical coverage for retirees and lifted price controls on prescription medication and private health plans, causing prices to spike by 250% and 118% respectively, official data shows. 'We've stopped buying milk, yogurt, anything that's not absolutely essential,' said Susana Pecora, 71, who lost the insurance plan that covered her husband's antipsychotic drugs when the price jumped 40% last year. Milei and Trump see eye-to-eye Milei campaigned on a promise to shrink the state two years before President Donald Trump and Elon Musk took up their own chainsaws. The Argentine has become a close ally of the Trump administration, including on health policy. Argentina has followed the U.S. out of the World Health Organization, and last month received a visit from U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. Meeting Kennedy in Buenos Aires, Argentine Health Minister Mario Lugones announced a review of Argentina's health system to align it with Kennedy's Make America Healthy Again movement. 'We have similar visions about the path forward,' Lugones said of Kennedy. Milei has not yet attempted to replace universal coverage with an insurance-based system, as he vowed on the campaign trail. But in stripping Argentines of coverage and increasing premiums and out-of-pocket expenses, he is moving Argentina closer to the U.S. model, said Macarena Sabin Paz, health team coordinator at Argentina's Center for Legal and Social Studies. 'We are beginning to see the idea ... where if you lose your job, or become seriously ill, you may have to sell your car, whatever you have, to pay for health care,' she said. Milei's staffing cuts have eviscerated agencies tasked with planning, financing and tracking immunization campaigns, disrupting data collection and jeopardizing the country's respected childhood vaccine program. The cuts have coincided with a measles outbreak that in April led to Argentina's first measles death in two decades. 'Argentina has been one of the most advanced South American countries and here we see it abandoning public health,' said Dr. Stanley Plotkin, an American physician who helped develop the measles vaccine in the 1960s. Milei's spokesperson, Manuel Adorni, did not respond to requests for comment. Lugones also did not respond to questions on the impact of policy changes. A tidal wave of cuts After decades of unbridled spending by left-wing populist governments that brought Argentina infamy for defaulting on its debts, Milei delivered on his campaign promises of taming extreme inflation and notching a fiscal surplus. But even experts who agree Argentina's health care system needed reform say the cutbacks have been so deep and fast that they've hit like a tidal wave. 'In terms of the destruction of the state, we've never experienced anything like this, not even during the military dictatorship,' said Fabio Nuñez, ex-coordinator of the National Directorate for HIV, Hepatitis and Tuberculosis who was among hundreds fired from the agency. Charged with leading prevention efforts and treatments for infectious diseases, the agency has lost 40% of its staff and 76% of its annual budget. Hospitals now face shortages of everything from virus testing supplies to medications to condoms. The cuts have coincided with a surge in sexually transmitted infections. Last year HIV cases spiked by 20% and syphilis by 50%. 'They're avoiding the expense now but will pay for it later as people seek emergency care,' said Cristian Pizzuti, a 31-year-old with HIV who documented 103 cases of patients deprived of their daily antiretroviral pills for weeks at a time last year. Pizzuti said he recently received expired medication and suffered a severe allergic reaction after being switched to a cheaper drug. Tuberculosis cases also climbed by 25% last year. TB clinics report delays in obtaining test results. 'As people go about their lives, waiting for results, they are spreading the disease to others,' said Dr. Santiago Jimenez, who treats HIV and TB patients in an impoverished Buenos Aires neighborhood. 'It's an epidemiological disaster.' Hospitals under strainFree public hospitals have become flooded with Argentines who dropped their private insurance due to increased premiums or who lost their job — and with it, their social security plans funded through payroll contributions. Buenos Aires facilities reported a 20%-30% increase in demand in the first quarter of 2025 compared to the same period last year. The strain was visible at the free public Rodolfo Rossi Hospital in La Plata last month, where crowds jostled in the outpatient clinic and long lines spilled from the pharmacy. Pharmacists have reported drug shortages as mass layoffs caused administrative chaos and the government froze a program that provided basic medications to Argentine public health centers. Silvana Mansilla, 43, spent half the day waiting to pick up her monthly supply of thyroid medication — which has doubled in price to $22 — only to find the hospital had run out. 'Where's the government? What are they doing about this?' she asked. With hiring frozen, doctors said they're handling double the patient load. Overwhelmed by ever-increasing workloads, Argentina's leading public Garrahan Pediatric Hospital in Buenos Aires has hemorrhaged 200 medical professionals since Milei took office. As annual inflation neared 200% last fall, their salaries lost half of their purchasing power. Doctors left for jobs abroad or better-paying work in private clinics. None were replaced. Medical residents ran a weeklong strike in May, displaying their pay slips for a month of 70-hour work weeks: $700. Waiting for treatment A lawsuit filed by patient advocacy groups said more than 60 cancer patients have died due to the government's suspension of the DADSE medication program, and over 1,500 patients were waiting for their drugs. A federal judge ordered the government to reinstate the drug deliveries, but it appealed, arguing that DADSE no longer exists. It said it had created a new, more efficient program to fulfill outstanding requests. But the timeline varies and sometimes the drugs don't come at all. Timing was everything for patients like Alexis Almirón. His medical records show the government drug bank received his request for an expensive medication to shrink his malignant tumor on Dec. 11, 2023, the day after Milei's inauguration. His doctor told the agency immediate treatment was urgently needed for the aggressive cancer. Months passed. His mother, Claudia Caballero, bombarded DADSE with desperate calls asking what was taking so long as Almirón's lymphoma spread from his neck to his brain and stomach. He vomited blood. He lost his eyesight. Caballero tried to crowd-source the $20,000 for a month's supply of the drug but couldn't raise enough. On March 12 last year, Almirón died at 22. 'They didn't give him the chance to choose to live,' Caballero said, her voice breaking. The day after she buried her son, Caballero received a call from the Health Ministry. They had good news, the caller said: Her son's medication had finally arrived.
